CC-122 + fluvoxamine

This is a **combination drug** comprised of **CC-122 (avadomide)** and **fluvoxamine**. - **CC-122 (avadomide)** is a novel **small-molecule cereblon E3 ligase modulator** with antitumor and immunomodulatory activity. It functions as an immunomodulatory agent, promoting antitumor effects through enhanced cereblon-mediated degradation of target proteins, with evidence of efficacy in various advanced malignancies, including non-Hodgkin lymphoma and multiple myeloma[4][2]. Developed by Celgene (now part of Bristol Myers Squibb), its mechanism involves targeting cereblon, which disrupts the activity of select proteins vital for cancer cell survival and immune modulation. - **Fluvoxamine** is a **selective serotonin reuptake inhibitor (SSRI)** approved for treating obsessive-compulsive disorder (OCD) and depression. Its action is inhibition of serotonin reuptake transporter (SERT), leading to increased serotonin in the synaptic cleft[1][3][5]. Fluvoxamine is also a potent inhibitor of CYP1A2, CYP2C19, and CYP3A4, impacting the metabolism of other drugs[1][3][5]. No evidence was found for a unique clinical rationale or program specifically examining the combination of **CC-122 (avadomide) and fluvoxamine**. Thus, this entry describes the properties and mechanisms of both agents as co-administered drugs, not as a unified combination product or regimen.

Other names

avadomide + fluvoxamine